What laboratory tests are recommended for the initial work‑up of a patient with central retinal vein occlusion?

Laboratory Testing for Central Retinal Vein Occlusion

All patients with CRVO should receive blood pressure measurement, intraocular pressure check, complete blood count, fasting glucose, and lipid panel as baseline screening 1.

Age-Stratified Approach to Laboratory Work-Up

Patients ≥50 Years Old (Standard Risk Profile)

For the majority of CRVO patients who are older than 50 years, the work-up should focus on common systemic vascular risk factors:

• Blood pressure (hypertension is a major risk factor)
• Fasting glucose or HbA1c (diabetes screening)
• Lipid panel (hyperlipidemia association)
• Complete blood count (polycythemia, thrombocytosis)
• Intraocular pressure (glaucoma is a CRVO risk factor)

These represent the most common laboratory abnormalities found in CRVO patients, with 74% having associated systemic vascular disease 2. The 2020 AAO Preferred Practice Pattern identifies older age as the main risk factor, with 90% of patients being over 50 at onset 3, 2.

Patients <50-56 Years Old (High-Risk for Thrombophilia)

In younger patients, particularly those under 50-56 years, expanded hypercoagulability testing is warranted because 58% will have a nontraditional risk factor and 27% will have laboratory evidence of hypercoagulability 3, 1.

The expanded panel should include:

• Homocysteine level (significantly elevated in young CRVO patients) 1
• Antiphospholipid antibodies (significantly more common in CRVO) 1
• Anticardiolipin antibodies 1
• Activated protein C resistance/Factor V Leiden (found in 32% of patients <45 years) 4
• Protein C activity 1
• Protein S activity 1
• Antithrombin III activity 1
• Factor VIII levels (elevated in 72% of RVO patients in one study) 4

Special Circumstances Requiring Extended Testing

Consider thrombophilia screening even in older patients when:

• Bilateral CRVO (highly unusual, suggests systemic hypercoagulable state) 1
• Personal history of prior thrombosis 1
• Family history of thrombosis 1
• Recurrent RVO in fellow eye 1

Additional Considerations

Rheologic Parameters

In patients with poor prognostic features, consider:

• Hematocrit levels (correlates with ischemia development) 5
• Fibrinogen levels (associated with poor outcomes) 5
• Erythrocyte aggregation (prognostic for visual outcome) 5

Atypical Presentations

When CRVO presents with unusual features (significant peripapillary exudates, peripheral vascular sheathing, young age without risk factors):

• Consider infectious etiologies including Bartonella henselae serology 6
• Evaluate for systemic vasculitis if accompanied by systemic symptoms 7

Common Pitfalls to Avoid

1. Don't skip basic screening in young patients - Even when ordering extensive thrombophilia panels, the basic metabolic screening (BP, glucose, lipids) remains essential as these can still be present in younger individuals.

2. Timing matters for hypercoagulability testing - Acute thrombotic events can temporarily alter coagulation parameters; ideally test after the acute phase or interpret cautiously.

3. Negative thrombophilia screening doesn't exclude hypercoagulability - Even with comprehensive testing, most young CRVO patients won't have an identifiable laboratory abnormality, as the cause remains multifactorial 1.

4. Don't forget cardiovascular risk stratification - CRVO patients have higher all-cause mortality due to cardiovascular disease, so identifying these risk factors has implications beyond the eye 3.